StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) KPIs and segments

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30240% above fair value
$137.78−5.59 (-3.90%)

Close on Nov 18, 2026Market cap $339.93BP/E 110.2Yield 2.38%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Merck · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của Merck: 118 chỉ số vận hành, trong đó có Keytruda (pembrolizumab, Welireg (belzutifan và Lynparza (olaparib, lấy từ 199 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Pharmaceutical($M)37
14,76014,34914,84315,61114,05013,63814,04214,94314,40814,00613,14114,263
United States($M)
8,8278,5128,6629,4938,3287,9277,7278,2277,3996,9366,6997,153
Keytruda($M)
7,9047,9068,3388,1427,9567,2057,8367,4297,2706,9476,6086,338
Non-US($M)
5,9335,8376,1816,1185,7225,7116,3156,7177,0097,0706,4427,110
Gardasil/Gardasil 9($M)
1,1691,0691,0311,7491,1261,3271,5512,3062,4782,2491,8712,585
Other pharmaceutical($M)
643775649953703865700638618632788568
ProQuad/M-M-R II/Varivax($M)
592538619684609539594703617570545713
Winrevair($M)
58852546736033628020014970000
Bridion($M)
497472500439461441449420455440429424
Keytruda Qlex($M)
46312800
Alliance revenue - Lynparza($M)
365341389379370312364337317292315299
Prevymis($M)
295272276266228208215208188174175157
Alliance revenue - Lenvima($M)
283256272258265258255251249255226260
Welireg($M)
271199220196162137160139126857254
Januvia($M)
258367302382372549232278405419547581
Ohtuvayre($M)
20413100
Capvaxive($M)
184142279244129107504700
Janumet($M)
171207199243251247256204224251240255
Vaxneuvance($M)
148202140226229230161239189219177214
RotaTeq($M)
134206119204121228139193163216185156
Alliance revenue - Adempas/Verquvo($M)
1261091301121231061091021069810892
Alliance Revenue - Reblozyl($M)
12214816413610711911010090717052
Delstrigo($M)
1017578778367696560565354
Adempas($M)
787883828068737272706665
Zerbaxa($M)
778287817470706462566153
Isentress/Isentress HD($M)
6059678286909210289111106119
Belsomra($M)
49474050457853465558
Pifeltro($M)
43434145404239423337
Pneumovax 23($M)
424538417568596185140
Dificid($M)
223425439683799692738774
Alliance revenue - Koselugo($M)
10161214434439
Lagevrio($M)
5285713883102121383110350192640
Simponi($M)
0000189172184171179
Remicade($M)
00004135394345
Intl($M)
7,0706,4427,110
Noxafil($M)
364145564651
Primaxin($M)
3941
Vaqta($M)
2969
Animal Health($M)5
1,7751,7911,5051,6151,6461,5881,3971,4871,4821,5111,2781,400
Non-US($M)
1,2401,2721,0561,1121,1471,0869539991,0271,037892938
Livestock($M)
1,0411,0649871,023961924889886837850807874
Companion Animal($M)
734727592685664601645661526
United States($M)
535519448504499502444487455474386462
Intl($M)
1,037892938
United States($M)
9,3679,1649,13910,0128,8368,5228,1888,7367,8767,4787,0877,715
Non-US($M)
7,1737,1097,2377,2306,8696,7977,2687,7168,0368,1077,3348,048
Europe, Middle East and Africa($M)
3,9203,8863,7913,6803,6593,4543,3803,5833,5153,5633,2763,327
Latin America($M)
875874854905859792868936858796788895
Asia Pacific (other than China and Japan)($M)
820738745764785689764823748724750781
Other($M)
640679781798595701701624612621599469
Japan($M)
5775557047126266698359386868216501,081
China($M)
4083903864054467028881,0171,8171,7721,4801,694
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
Pharmaceutical($M)
13,02912,79613,00213,94712,44912,06512,53313,03912,70012,300
Animal Health($M)
1,0601,116824905987988766874870898
Pharmaceutical($M)
11,61211,51911,49012,53811,10310,71210,88211,54711,20010,9049,48010,407
Animal Health($M)
636722394511593634364510508555284421
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide sales ($M)($M)5
7,9047,9068,3378,1427,9567,2057,8367,4297,2706,9476,6086,338
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — U.S. sales ($M)($M)1
4,6114,5994,8924,8794,7494,3084,8414,5004,4124,1193,9723,795
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — U.S. reported growth YoY (%)(%)
-3.0%1.0%8.0%8.0%5.0%22.0%19.0%14.0%18.0%18.0%14.0%
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — International sales ($M)($M)1
3,2933,3073,4453,2633,2072,8972,9962,9292,8582,8282,6362,543
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — International reported growth YoY (%)(%)
3.0%15.0%11.0%12.0%2.0%14.0%15.0%19.0%22.0%27.0%21.0%
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide reported growth YoY (%)(%)
-1.0%6.0%10.0%9.0%4.0%19.0%17.0%16.0%20.0%21.0%17.0%
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-2.0%5.0%8.0%9.0%21.0%21.0%24.0%22.0%17.0%
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — Worldwide sales ($M)($M)2
46312800
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — U.S. sales ($M)($M)
39510600
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — International sales ($M)($M)
682100
Welireg (belzutifan — HIF-2α inhibitor) — Worldwide sales ($M)($M)4
271199220196162137160139126857254
Welireg (belzutifan — HIF-2α inhibitor) — U.S. sales ($M)($M)1
214152181161138123146127116776851
Welireg (belzutifan — HIF-2α inhibitor) — U.S. reported growth YoY (%)(%)
55.0%24.0%27.0%19.0%59.0%114.0%148.0%138.0%89.0%
Welireg (belzutifan — HIF-2α inhibitor) — International sales ($M)($M)
574739352415141210743
Welireg (belzutifan — HIF-2α inhibitor) — Worldwide reported growth YoY (%)(%)
67.0%37.0%42.0%29.0%62.0%122.0%156.0%150.0%102.0%79.0%43.0%
Welireg (belzutifan — HIF-2α inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
67.0%37.0%41.0%29.0%123.0%150.0%102.0%78.0%43.0%
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide sales ($M)($M)4
365341389379370312365337317292315299
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — U.S. sales ($M)($M)1
167149180184174145177161153135168153
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — U.S. reported growth YoY (%)(%)
-4.0%1.0%14.0%14.0%7.0%5.0%5.0%6.0%-4.0%7.0%7.0%
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — International sales ($M)($M)1
198192209195195168187177165157147146
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — International reported growth YoY (%)(%)
2.0%12.0%11.0%19.0%7.0%28.0%21.0%-1.0%18.0%9.0%4.0%
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide reported growth YoY (%)(%)
-1.0%7.0%12.0%17.0%7.0%16.0%13.0%2.0%6.0%8.0%5.0%
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-2.0%4.0%12.0%15.0%18.0%4.0%7.0%8.0%6.0%
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide sales ($M)($M)4
283256272258265258255251249255226260
Lenvima (lenvatinib — Eisai oncology alliance revenue) — U.S. sales ($M)($M)1
194176191177183186182173177173181160
Lenvima (lenvatinib — Eisai oncology alliance revenue) — U.S. reported growth YoY (%)(%)
6.0%5.0%2.0%3.0%8.0%1.0%9.0%8.0%13.0%18.0%13.0%
Lenvima (lenvatinib — Eisai oncology alliance revenue) — International sales ($M)($M)1
9080808183727378738245100
Lenvima (lenvatinib — Eisai oncology alliance revenue) — International reported growth YoY (%)(%)
8.0%11.0%4.0%14.0%-12.0%63.0%-22.0%-7.0%3.0%-28.0%67.0%
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide reported growth YoY (%)(%)
7.0%7.0%3.0%6.0%1.0%13.0%-3.0%3.0%10.0%5.0%29.0%
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
6.0%6.0%2.0%5.0%14.0%4.0%10.0%5.0%30.0%
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide sales ($M)($M)4
12214816413610711911010090717052
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. sales ($M)($M)1
9812813311188101888275586043
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. reported growth YoY (%)(%)
11.0%51.0%35.0%18.0%72.0%47.0%93.0%110.0%93.0%68.0%34.0%
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — International sales ($M)($M)1
252031251918221815121010
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — International reported growth YoY (%)(%)
31.0%37.0%40.0%24.0%47.0%124.0%83.0%36.0%74.0%42.0%
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide reported growth YoY (%)(%)
15.0%48.0%36.0%19.0%68.0%58.0%91.0%92.0%66.0%69.0%35.0%
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
15.0%48.0%36.0%19.0%58.0%92.0%66.0%69.0%35.0%
Koselugo (selumetinib — AstraZeneca NF1 alliance revenue) — Worldwide ($M)($M)
01322711595563937382326
Total Vaccines Franchise — Worldwide sales ($M)($M)
01325797035955465927157452,9624,002
Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide sales ($M)($M)5
1,1691,0691,0311,7491,1261,3271,5502,3062,4782,2491,8712,585
Gardasil / Gardasil 9 (HPV recombinant vaccine) — U.S. sales ($M)($M)1
5424854061,1545455363801,020536488365838
Gardasil / Gardasil 9 (HPV recombinant vaccine) — U.S. reported growth YoY (%)(%)
-1.0%7.0%13.0%2.0%10.0%4.0%22.0%17.0%
Gardasil / Gardasil 9 (HPV recombinant vaccine) — International sales ($M)($M)1
6265856255955817901,1701,2851,9411,7611,5061,746
Gardasil / Gardasil 9 (HPV recombinant vaccine) — International reported growth YoY (%)(%)
8.0%-47.0%-54.0%-70.0%-55.0%-22.0%-26.0%13.0%
Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide reported growth YoY (%)(%)
4.0%-34.0%-24.0%-55.0%-41.0%-17.0%-11.0%1.0%14.0%
Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
3.0%-35.0%-25.0%-55.0%-18.0%4.0%17.0%
Gardasil / Gardasil 9 — China sales ($M)($M)
0001934465171,3121,253
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide sales ($M)($M)7
592538619684609539594703617570545713
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. sales ($M)($M)1
438409427554481423419572490438402567
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. reported growth YoY (%)(%)
-9.0%2.0%-3.0%-2.0%-3.0%4.0%1.0%4.0%
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — International sales ($M)($M)1
154129192130128116175131127133143146
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — International reported growth YoY (%)(%)
20.0%9.0%-1.0%1.0%-12.0%23.0%-10.0%24.0%
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide reported growth YoY (%)(%)
-3.0%4.0%-3.0%-1.0%-5.0%9.0%-1.0%6.0%8.0%
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-3.0%3.0%-3.0%-2.0%9.0%7.0%8.0%
Varivax (varicella live virus vaccine) — Worldwide sales ($M)($M)2
260235264288240249274301266262252325
Varivax — Worldwide reported growth YoY (%)(%)
8.0%-6.0%-4.0%-10.0%-5.0%-7.0%4.0%11.0%16.0%
Varivax — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
8.0%-7.0%-5.0%-10.0%-4.0%-7.0%5.0%11.0%15.0%
ProQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M)($M)2
235198262273273121203274239204192267
ProQuad — Worldwide reported growth YoY (%)(%)
-14.0%64.0%15.0%-41.0%3.0%7.0%8.0%1.0%
ProQuad — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-15.0%60.0%-1.0%14.0%-40.0%3.0%8.0%7.0%1.0%
M-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M)($M)2
961059312395168118129113104101122
M-M-R II — Worldwide reported growth YoY (%)(%)
1.0%-38.0%-5.0%-15.0%62.0%5.0%8.0%2.0%-2.0%
M-M-R II — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
1.0%-39.0%-6.0%-16.0%63.0%6.0%9.0%2.0%-4.0%
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide sales ($M)($M)4
148202140226229230161239189219176214
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. sales ($M)($M)1
69123501341361396413799161138182
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. reported growth YoY (%)(%)
-50.0%-22.0%-1.0%38.0%-14.0%-53.0%-25.0%-33.0%72.0%5.0%
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — International sales ($M)($M)
8078909193929610390583833
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide reported growth YoY (%)(%)
-35.0%-13.0%-6.0%21.0%5.0%-9.0%12.0%13.0%106.0%28.0%
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-36.0%-16.0%-7.0%20.0%-9.0%16.0%106.0%26.0%
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — Worldwide sales ($M)($M)2
18414227924412910750975047
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — U.S. sales ($M)($M)
138118258238129106494700
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — International sales ($M)($M)
4523217010000
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide sales ($M)($M)4
134206119204121228139193163216185156
RotaTeq (rotavirus live oral pentavalent vaccine) — U.S. sales ($M)($M)1
84165601416016484131107149112108
RotaTeq (rotavirus live oral pentavalent vaccine) — U.S. reported growth YoY (%)(%)
39.0%-28.0%8.0%-44.0%10.0%-25.0%21.0%15.0%-17.0%37.0%-30.0%
RotaTeq (rotavirus live oral pentavalent vaccine) — International sales ($M)($M)1
504259636164556256677348
RotaTeq (rotavirus live oral pentavalent vaccine) — International reported growth YoY (%)(%)
-18.0%8.0%2.0%9.0%-4.0%-25.0%28.0%50.0%-43.0%28.0%-53.0%
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide reported growth YoY (%)(%)
10.0%-14.0%6.0%-26.0%5.0%-25.0%24.0%25.0%-27.0%34.0%-39.0%
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
9.0%-15.0%5.0%-26.0%-25.0%26.0%-27.0%33.0%-39.0%
Vaqta (hepatitis A vaccine, legacy) — Worldwide sales ($M)($M)2
2969
Vaqta (hepatitis A vaccine, legacy) — U.S. sales ($M)($M)
2832
Vaqta (hepatitis A vaccine, legacy) — International sales ($M)($M)
137
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — Worldwide sales ($M)($M)2
5885254673603362802002001497000
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — U.S. sales ($M)($M)
52247743233532326819214770000
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — International sales ($M)($M)
664835251212930000
Ohtuvayre (ensifentrine — COPD maintenance therapy, acquired via Verona Pharma Q4 2025) — Worldwide sales ($M)($M)1
20413100
Ohtuvayre (ensifentrine — COPD maintenance therapy, acquired via Verona Pharma Q4 2025) — International sales ($M)($M)
0000
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide sales ($M)($M)5
1261091291121231061091021069810892
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — U.S. sales ($M)($M)1
1121091121031089710596989010296
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — U.S. reported growth YoY (%)(%)
4.0%7.0%8.0%10.0%8.0%3.0%-1.0%41.0%8.0%20.0%13.0%
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International sales ($M)($M)1
14017815957886-4
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International reported growth YoY (%)(%)
-1.0%25.0%89.0%12.0%-27.0%-51.0%
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide reported growth YoY (%)(%)
3.0%18.0%9.0%16.0%8.0%1.0%11.0%56.0%-1.0%31.0%5.0%
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
3.0%18.0%9.0%16.0%1.0%56.0%-1.0%31.0%5.0%
Adempas (riociguat — direct Merck territory sales) — Worldwide sales ($M)($M)4
787883828068737272706665
Adempas (riociguat — direct Merck territory sales) — U.S. sales ($M)($M)
000000000000
Adempas (riociguat — direct Merck territory sales) — International sales ($M)($M)
787883828068737272706665
Adempas (riociguat — direct Merck territory sales) — Worldwide reported growth YoY (%)(%)
-2.0%14.0%14.0%10.0%11.0%11.0%18.0%15.0%15.0%
Adempas (riociguat — direct Merck territory sales) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-4.0%9.0%7.0%6.0%9.0%15.0%18.0%11.0%11.0%
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide sales ($M)($M)4
497472499439461441449420455440429424
Bridion (sugammadex — neuromuscular blockade reversal) — U.S. sales ($M)($M)1
460427451392411378382339351329315265
Bridion (sugammadex — neuromuscular blockade reversal) — U.S. reported growth YoY (%)(%)
12.0%18.0%15.0%17.0%15.0%21.0%28.0%17.0%19.0%22.0%14.0%
Bridion (sugammadex — neuromuscular blockade reversal) — International sales ($M)($M)1
3745494750636781104111113159
Bridion (sugammadex — neuromuscular blockade reversal) — International reported growth YoY (%)(%)
-25.0%-28.0%-42.0%-52.0%-43.0%-41.0%-49.0%-49.0%-47.0%-38.0%-17.0%
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide reported growth YoY (%)(%)
8.0%11.0%5.0%1.0%5.0%-1.0%-9.0%-10.0%-3.0%
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
8.0%11.0%4.0%1.0%5.0%-8.0%-8.0%-3.0%
Prevymis (letermovir — CMV prophylaxis) — Worldwide sales ($M)($M)4
295272275266228208215208188174175157
Prevymis (letermovir — CMV prophylaxis) — U.S. sales ($M)($M)1
14713513012811510210610190747870
Prevymis (letermovir — CMV prophylaxis) — U.S. reported growth YoY (%)(%)
28.0%23.0%27.0%27.0%37.0%36.0%43.0%47.0%37.0%49.0%43.0%
Prevymis (letermovir — CMV prophylaxis) — International sales ($M)($M)1
148138146138113106109107981009887
Prevymis (letermovir — CMV prophylaxis) — International reported growth YoY (%)(%)
31.0%33.0%29.0%16.0%6.0%12.0%24.0%19.0%33.0%50.0%35.0%
Prevymis (letermovir — CMV prophylaxis) — Worldwide reported growth YoY (%)(%)
29.0%28.0%28.0%21.0%19.0%23.0%32.0%31.0%35.0%49.0%38.0%
Prevymis (letermovir — CMV prophylaxis) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
28.0%26.0%25.0%20.0%23.0%35.0%39.0%49.0%38.0%
Dificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M)($M)4
223425439683799692738774
Dificid (fidaxomicin — C. difficile infection) — U.S. sales ($M)($M)1
112417308372728379687569
Dificid (fidaxomicin — C. difficile infection) — U.S. reported growth YoY (%)(%)
-87.0%-76.0%-64.0%4.0%6.0%-4.0%20.0%16.0%10.0%32.0%-3.0%
Dificid (fidaxomicin — C. difficile infection) — International sales ($M)($M)1
12108131311713125125
Dificid (fidaxomicin — C. difficile infection) — International reported growth YoY (%)(%)
-11.0%13.0%-2.0%8.0%117.0%-42.0%190.0%56.0%49.0%17.0%-20.0%
Dificid (fidaxomicin — C. difficile infection) — Worldwide reported growth YoY (%)(%)
-77.0%-68.0%-55.0%5.0%13.0%-9.0%31.0%20.0%12.0%30.0%-4.0%
Dificid (fidaxomicin — C. difficile infection) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-77.0%-68.0%-55.0%5.0%-9.0%20.0%12.0%30.0%-4.0%
Zerbaxa (ceftolozane and tazobactam) — Worldwide sales ($M)($M)4
778287817470706462566153
Zerbaxa (ceftolozane and tazobactam) — U.S. sales ($M)($M)1
445250494542403933333329
Zerbaxa (ceftolozane and tazobactam) — U.S. reported growth YoY (%)(%)
-3.0%25.0%25.0%35.0%27.0%23.0%34.0%12.0%23.0%31.0%19.0%
Zerbaxa (ceftolozane and tazobactam) — International sales ($M)($M)1
343036322928302628232824
Zerbaxa (ceftolozane and tazobactam) — International reported growth YoY (%)(%)
14.0%23.0%25.0%5.0%20.0%4.0%6.0%17.0%1.0%18.0%27.0%
Zerbaxa (ceftolozane and tazobactam) — Worldwide reported growth YoY (%)(%)
4.0%24.0%25.0%21.0%24.0%14.0%22.0%14.0%13.0%25.0%23.0%
Zerbaxa (ceftolozane and tazobactam) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
2.0%23.0%24.0%21.0%16.0%18.0%15.0%23.0%22.0%
Primaxin (imipenem and cilastatin, legacy) — Worldwide sales ($M)($M)4
3941
Primaxin (imipenem and cilastatin, legacy) — U.S. sales ($M)($M)
-10
Primaxin (imipenem and cilastatin, legacy) — International sales ($M)($M)
3841
Primaxin (imipenem and cilastatin, legacy) — Worldwide reported growth YoY (%)(%)
-28.0%-35.0%
Primaxin (imipenem and cilastatin, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-28.0%-31.0%
Noxafil (posaconazole, legacy) — Worldwide sales ($M)($M)4
364145564651
Noxafil (posaconazole, legacy) — U.S. sales ($M)($M)1
-210844
Noxafil (posaconazole, legacy) — U.S. reported growth YoY (%)(%)
-149.0%-85.0%-43.0%-72.0%-71.0%
Noxafil (posaconazole, legacy) — International sales ($M)($M)1
374044484347
Noxafil (posaconazole, legacy) — International reported growth YoY (%)(%)
-12.0%-15.0%4.0%-7.0%-3.0%
Noxafil (posaconazole, legacy) — Worldwide reported growth YoY (%)(%)
-23.0%-20.0%-20.0%-7.0%-21.0%-18.0%
Noxafil (posaconazole, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-17.0%-9.0%4.0%-16.0%-12.0%
Total Diabetes Franchise (Januvia + Janumet) — Worldwide sales ($M)2
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide sales ($M)($M)4
258367302382372549232278405419547581
Januvia (sitagliptin — DPP-4 inhibitor) — U.S. sales ($M)($M)1
1492521802582163444167177183309328
Januvia (sitagliptin — DPP-4 inhibitor) — U.S. reported growth YoY (%)(%)
-31.0%22.0%88.0%-87.0%-80.0%-27.0%-32.0%6.0%-1.0%
Januvia (sitagliptin — DPP-4 inhibitor) — International sales ($M)($M)1
109116122124155204191211227236239252
Januvia (sitagliptin — DPP-4 inhibitor) — International reported growth YoY (%)(%)
-30.0%-36.0%-42.0%-32.0%-13.0%-20.0%-16.0%-15.0%-16.0%-12.0%-34.0%
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide reported growth YoY (%)(%)
-31.0%30.0%37.0%-8.0%31.0%-58.0%-52.0%-21.0%-24.0%-2.0%-19.0%
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-30.0%30.0%37.0%-8.0%-56.0%-16.0%-21.0%-2.0%-17.0%
Janumet (sitagliptin and metformin HCl) — Worldwide sales ($M)($M)4
171207199243251247255204224251240255
Janumet (sitagliptin and metformin HCl) — U.S. sales ($M)($M)1
286857786865911517394143
Janumet (sitagliptin and metformin HCl) — U.S. reported growth YoY (%)(%)
-59.0%-37.0%68.0%122.0%-67.0%-80.0%-32.0%-58.0%-52.0%
Janumet (sitagliptin and metformin HCl) — International sales ($M)($M)1
143139142165184182164190208212198211
Janumet (sitagliptin and metformin HCl) — International reported growth YoY (%)(%)
-22.0%-14.0%-13.0%-12.0%-14.0%-17.0%-10.0%-24.0%-22.0%-22.0%-35.0%
Janumet (sitagliptin and metformin HCl) — Worldwide reported growth YoY (%)(%)
-32.0%-22.0%19.0%12.0%-2.0%7.0%-20.0%-37.0%-24.0%-32.0%-39.0%
Janumet (sitagliptin and metformin HCl) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-33.0%-22.0%20.0%14.0%11.0%-32.0%-20.0%-32.0%-38.0%
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide sales ($M)($M)4
5285713883102121383110350193640
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — U.S. sales ($M)($M)
1161124303532841545100
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — International sales ($M)($M)1
3124511452678829995305183640
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — International reported growth YoY (%)(%)
-94.0%-49.0%-62.0%-45.0%-78.0%-52.0%-53.0%-23.0%
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide reported growth YoY (%)(%)
-95.0%-53.0%-64.0%-25.0%-71.0%-37.0%-46.0%-11.0%-77.0%47.0%
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-95.0%-53.0%-65.0%-27.0%-37.0%-42.0%-5.0%-76.0%51.0%
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide sales ($M)($M)4
6059678286909210289111105119
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M)($M)1
363537444851385443505058
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. reported growth YoY (%)(%)
-26.0%-3.0%-18.0%13.0%2.0%-23.0%-6.0%-24.0%-3.0%
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — International sales ($M)($M)1
242430373839534846615661
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — International reported growth YoY (%)(%)
-36.0%-44.0%-23.0%-18.0%-35.0%-4.0%-21.0%-42.0%-14.0%
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide reported growth YoY (%)(%)
-30.0%-27.0%-20.0%-3.0%-19.0%-13.0%-14.0%-35.0%-10.0%
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-31.0%-28.0%-21.0%-4.0%-7.0%-31.0%-7.0%
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide sales ($M)($M)4
1017579778367696560565454
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. sales ($M)($M)1
131014131415141514121213
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. reported growth YoY (%)(%)
-7.0%-1.0%-13.0%-5.0%28.0%19.0%15.0%13.0%9.0%
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — International sales ($M)($M)1
886565647052555045444240
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — International reported growth YoY (%)(%)
27.0%19.0%29.0%55.0%17.0%30.0%23.0%21.0%34.0%
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide reported growth YoY (%)(%)
21.0%15.0%19.0%40.0%19.0%28.0%21.0%19.0%28.0%
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
17.0%9.0%13.0%35.0%29.0%23.0%30.0%
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide sales ($M)($M)4
42434145404239423337
Pifeltro (doravirine — HIV-1 NNRTI) — U.S. sales ($M)($M)1
26292532263127292327
Pifeltro (doravirine — HIV-1 NNRTI) — U.S. reported growth YoY (%)(%)
-3.0%-7.0%-4.0%8.0%16.0%12.0%-1.0%22.0%
Pifeltro (doravirine — HIV-1 NNRTI) — International sales ($M)($M)1
17141613131212131010
Pifeltro (doravirine — HIV-1 NNRTI) — International reported growth YoY (%)(%)
23.0%21.0%26.0%2.0%29.0%20.0%15.0%25.0%
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide reported growth YoY (%)(%)
6.0%1.0%5.0%7.0%20.0%14.0%3.0%23.0%
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
4.0%-1.0%4.0%20.0%4.0%23.0%
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M)($M)2
0000543189172184710171
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%)(%)
-4.0%2.0%3.0%3.0%
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-24.0%-2.0%1.0%-2.0%-2.0%
Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M)($M)1
000011441353918743
Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%)(%)
-27.0%-24.0%-1.0%-8.0%
Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide sales ($M)($M)4
49474050457853465458
Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. sales ($M)($M)1
22281813192019152123
Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. reported growth YoY (%)(%)
18.0%40.0%-1.0%-10.0%-12.0%-12.0%-12.0%-9.0%10.0%12.0%
Belsomra (suvorexant — insomnia orexin receptor antagonist) — International sales ($M)($M)1
27192137265834323335
Belsomra (suvorexant — insomnia orexin receptor antagonist) — International reported growth YoY (%)(%)
1.0%-67.0%-37.0%16.0%-20.0%66.0%-18.0%-21.0%-17.0%-15.0%
Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide reported growth YoY (%)(%)
8.0%-40.0%-24.0%8.0%-17.0%35.0%-16.0%-17.0%-8.0%-6.0%
Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
9.0%-40.0%-26.0%-17.0%-8.0%-11.0%-6.0%-4.0%
Other Pharmaceutical Products — Worldwide sales ($M)($M)5
6417747701,004703865699638618632576568
Other Pharmaceutical Products — U.S. sales ($M)($M)1
150166126239184184121167190165137189
Other Pharmaceutical Products — U.S. reported growth YoY (%)(%)
-18.0%4.0%43.0%-28.0%12.0%26.0%13.0%20.0%-8.0%-20.0%2.0%
Other Pharmaceutical Products — International sales ($M)($M)1
489608531716520545581466430467438381
Other Pharmaceutical Products — International reported growth YoY (%)(%)
-6.0%-9.0%54.0%5.0%17.0%24.0%12.0%-4.0%-8.0%11.0%-14.0%
Other Pharmaceutical Products — Worldwide reported growth YoY (%)(%)
-9.0%-6.0%50.0%-6.0%16.0%25.0%13.0%2.0%-8.0%2.0%-9.0%
Other Pharmaceutical Products — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-9.0%-5.0%49.0%-7.0%25.0%6.0%-6.0%2.0%-7.0%
Upfront & milestone payments received for out-licensed products — Worldwide ($M)($M)
0132271159515151561
Animal Health Segment — Worldwide sales ($M)($M)6
1,7751,7911,5051,6151,6461,5881,3971,4871,4821,5111,2781,400
Animal Health Segment — U.S. sales ($M)($M)1
535448504499502444487455474387462
Animal Health Segment — U.S. reported growth YoY (%)(%)
7.0%1.0%3.0%9.0%6.0%15.0%6.0%-4.0%-2.0%-2.0%-3.0%
Animal Health Segment — International sales ($M)($M)1
1,2401,0561,1121,1471,0869539991,0271,037891938
Animal Health Segment — International reported growth YoY (%)(%)
8.0%11.0%11.0%12.0%5.0%7.0%6.0%5.0%3.0%7.0%5.0%
Animal Health Segment — Worldwide reported growth YoY (%)(%)
8.0%8.0%9.0%11.0%5.0%9.0%6.0%2.0%1.0%4.0%2.0%
Animal Health Segment — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
5.0%6.0%7.0%11.0%13.0%6.0%4.0%4.0%2.0%
Animal Health — Livestock (cattle, poultry, swine & aqua) — Worldwide sales ($M)($M)4
1,0411,0649871,023961924889886837850808874
Animal Health — Livestock (cattle, poultry, swine & aqua) — U.S. sales ($M)($M)1
202211209213190194203194168166158205
Animal Health — Livestock (cattle, poultry, swine & aqua) — U.S. reported growth YoY (%)(%)
6.0%3.0%10.0%13.0%17.0%28.0%-5.0%2.0%-5.0%-16.0%10.0%
Animal Health — Livestock (cattle, poultry, swine & aqua) — International sales ($M)($M)1
838853777811771730686692669683649669
Animal Health — Livestock (cattle, poultry, swine & aqua) — International reported growth YoY (%)(%)
9.0%13.0%17.0%15.0%7.0%6.0%3.0%4.0%1.0%4.0%4.0%
Animal Health — Livestock (cattle, poultry, swine & aqua) — Worldwide reported growth YoY (%)(%)
8.0%11.0%16.0%15.0%9.0%10.0%1.0%4.0%-1.0%5.0%
Animal Health — Livestock (cattle, poultry, swine & aqua) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
6.0%9.0%14.0%16.0%14.0%11.0%4.0%7.0%
Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide sales ($M)($M)5
734727518592685664508601645661470526
Animal Health — Companion Animal (vaccines & parasiticides) — U.S. sales ($M)($M)1
333308239291309308241293287308229257
Animal Health — Companion Animal (vaccines & parasiticides) — U.S. reported growth YoY (%)(%)
8.0%-1.0%-1.0%8.0%5.0%14.0%-7.0%10.0%-11.0%
Animal Health — Companion Animal (vaccines & parasiticides) — International sales ($M)($M)1
402419279301376356267307358354242269
Animal Health — Companion Animal (vaccines & parasiticides) — International reported growth YoY (%)(%)
7.0%4.0%-2.0%5.0%1.0%11.0%14.0%6.0%6.0%16.0%6.0%
Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide reported growth YoY (%)(%)
7.0%2.0%-2.0%6.0%8.0%14.0%-1.0%3.0%13.0%-3.0%
Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
5.0%0.0%-3.0%6.0%10.0%1.0%4.0%12.0%-4.0%
Bravecto (fluralaner parasiticides line) — Quarterly sales Q1–Q3 ($M; Q4 not separately disclosed)($M)1
359379262335266235
Bravecto — Worldwide reported growth YoY (%)(%)
7.0%16.0%-1.0%1.0%-3.0%
Pharmaceutical Segment — Worldwide sales ($M)($M)11
14,76014,34914,84315,61114,05013,63814,04214,94314,40814,00613,14114,263
Pharmaceutical Sales — United States ($M)($M)2
8,8278,5128,6629,4938,3287,9277,7288,2277,3996,9366,6987,153
Pharmaceutical Sales — United States share of Pharmaceutical revenue (%)(%)
59.8%59.3%58.4%60.8%59.3%58.1%55.0%55.1%51.4%49.5%51.0%50.1%
Pharmaceutical Segment — U.S. reported growth YoY (%)(%)
6.0%12.0%15.0%13.0%14.0%15.0%15.0%13.0%13.0%14.0%8.0%
Pharmaceutical Sales — Europe ($M)($M)1
2,8012,7252,8392,6752,5512,3842,4982,6202,5722,5552,4912,497
Pharmaceutical Sales — Europe share of Pharmaceutical revenue (%)(%)
19.0%19.0%19.1%17.1%18.2%17.5%17.8%17.5%17.9%18.2%19.0%17.5%
Pharmaceutical Sales — China ($M)($M)1
3683533643774076688649961,7901,7441,4561,674
Pharmaceutical Sales — China share of Pharmaceutical revenue (%)(%)
2.5%2.5%2.5%2.4%2.9%4.9%6.2%6.7%12.4%12.5%11.1%11.7%
Pharmaceutical Sales — Japan ($M)($M)1
5585356846936046518139196648026291,062
Pharmaceutical Sales — Japan share of Pharmaceutical revenue (%)(%)
3.8%3.7%4.6%4.4%4.3%4.8%5.8%6.2%4.6%5.7%4.8%7.4%
Pharmaceutical Sales — Asia Pacific (other than China and Japan) ($M)($M)1
636569586593609535612669595580616636
Pharmaceutical Sales — Asia Pacific (other than China and Japan) share of Pharmaceutical revenue (%)(%)
4.3%4.0%4.0%3.8%4.3%3.9%4.4%4.5%4.1%4.1%4.7%4.5%
Pharmaceutical Sales — Latin America ($M)($M)1
636624644691654589680730661601596696
Pharmaceutical Sales — Latin America share of Pharmaceutical revenue (%)(%)
4.3%4.3%4.3%4.4%4.7%4.3%4.8%4.9%4.6%4.3%4.5%4.9%
Pharmaceutical Sales — Eastern Europe / Middle East / Africa ($M)($M)1
408413348365451435348400353395299301
Pharmaceutical Sales — Eastern Europe / Middle East / Africa share of Pharmaceutical revenue (%)(%)
2.8%2.9%2.3%2.3%3.2%3.2%2.5%2.7%2.4%2.8%2.3%2.1%
Pharmaceutical Sales — Canada ($M)($M)1
154137153134135125144133143138138133
Pharmaceutical Sales — Canada share of Pharmaceutical revenue (%)(%)
1.0%1.0%1.0%0.9%1.0%0.9%1.0%0.9%1.0%1.0%1.1%0.9%
Pharmaceutical Sales — Other Countries ($M)($M)1
372481563590311324355249231255218111
Pharmaceutical Sales — Other Countries share of Pharmaceutical revenue (%)(%)
2.5%3.3%3.8%3.9%2.1%2.4%2.5%1.5%1.6%1.9%1.5%0.9%
Pharmaceutical Segment — Worldwide reported growth YoY (%)(%)
5.0%6.0%4.0%-2.0%-3.0%7.0%5.0%7.0%10.0%8.0%10.0%
Pharmaceutical Segment — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
4.0%4.0%3.0%-3.0%8.0%11.0%13.0%8.0%11.0%
Total Company Sales — Worldwide ($M)($M)5
16,60716,28616,40017,27615,80615,52915,62416,65716,11215,77514,63015,962
Total Company Sales — United States ($M)($M)1
9,3679,1649,13910,0128,8368,5228,1888,7367,8767,4787,0887,715
Total Company Sales — U.S. reported growth YoY (%)(%)
6.0%12.0%15.0%12.0%14.0%16.0%13.0%12.0%12.0%13.0%5.0%
Total Company Sales — International ($M)($M)1
7,2407,1227,2617,2646,9697,0077,4367,9228,2368,2977,5428,247
Total Company Sales — International reported growth YoY (%)(%)
4.0%-2.0%-8.0%-15.0%-16.0%-1.0%-4.0%3.0%6.0%8.0%
Other Revenues (alliance, royalty & third-party supply) — Worldwide ($M)($M)2
721465250110303185227222258211299
Other Revenues — U.S. ($M)($M)
52915993162222683100
Other Revenues — International ($M)($M)
672434100210169206200190208199
Total Company Sales — Worldwide reported growth YoY (%)(%)
5.0%5.0%4.0%-2.0%-2.0%7.0%4.0%7.0%9.0%6.0%7.0%
Total Company Sales — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
4.0%4.0%3.0%-2.0%9.0%11.0%12.0%7.0%9.0%
U.S. Aggregate Customer Discounts (Chargebacks & Rebates) Provision ($M)($M)
2,5002,5002,8002,6002,5002,1003,2003,6003,3003,2003,1003,100
Collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M)($M)6
8484858486831338282828182
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current receivables from partner ($M)($M)
375401451436411358424375349334341
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Noncurrent receivables from partner ($M)($M)
1251251250
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current payables / liabilities to partner ($M)($M)
612641215713615615617256257
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M)
8484858486831338282828182
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Net R&D cost-sharing expense ($M)($M)
95531612201918201423
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Commercialization / SG&A expense sharing ($M)($M)
252430314032443943394944
Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M)($M)4
1313606060606060606061137
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Current receivables from partner ($M)($M)
281252271258265263257252245255226
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M)
1313606060606060606061137
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Net R&D cost-sharing expense ($M)($M)
021235346855
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Commercialization / SG&A expense sharing ($M)($M)
292735333531394041394446
Collaboration — Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) ($M)($M)5
676766716158625961625953
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Current receivables from partner ($M)($M)
166162167168173160160166170155156
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Current payables / liabilities to partner ($M)($M)
868781938883828281748082
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M)
676766716158625961625953
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Net R&D cost-sharing expense ($M)($M)
10171112024202728281426
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Commercialization / SG&A expense sharing ($M)($M)
111217222929232926333133
Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M)($M)4
181160-1671931280065695,5000
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current receivables from partner ($M)($M)
27221517211380
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M)($M)
10085113869850803817811801817800
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Net R&D cost-sharing expense ($M)($M)
1811601451101931281249465695,5000
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Commercialization / SG&A expense sharing ($M)($M)
121278495514330
Collaboration — Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) ($M)($M)4
94901039690861039393696566
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Current receivables from partner ($M)($M)
1540235232228198172135110
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Current payables / liabilities to partner ($M)($M)
00131322375768737263
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Net R&D cost-sharing expense ($M)($M)
94901039690861039393696566
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Commercialization / SG&A expense sharing ($M)($M)
988766554222
Collaboration — Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) ($M)($M)2
145457814453632049619190348
Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M)
145457814453632049619190348
Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Commercialization / SG&A expense sharing ($M)($M)
91115111413141116162521
Research & Development Expense — Pharmaceutical Segment ($M)($M)3
0000000000
Research & Development Expense — Animal Health Segment ($M)($M)
12011212511811095109959190
Merck Research Laboratories (MRL) Direct Human Health R&D ($B)
2.80
Acquired In-Process R&D (IPR&D) & Asset Acquisition Charges ($M)($M)
5,2718,54000007002,100065610,2170
Non-GAAP Diluted Earnings per Share ($)($)9
-0.13-1.282.042.582.132.221.721.572.282.070.032.13
Non-GAAP Net Income Attributable to Merck & Co., Inc. ($M)($M)
-1,005-3,1565,0886,4485,3665,6114,3723,9855,8095,279665,427
Non-GAAP Income Before Taxes ($M)($M)3
550-2,2026,0107,4506,3116,5485,2205,1066,7676,296-1,5736,391
Total Pre-Tax Non-GAAP Adjustments ($M)($M)
-1,233-1,332-2,590344-1,312107-1,050-1,0164911661
Acquisition & Divestiture-Related Pre-Tax Charges ($M)($M)
1911,0461,107611,233
Restructuring Pre-Tax Charges ($M)($M)
1,2331801,2771,31261
Non-GAAP Cost of Sales ($M)($M)1
3,1442,9443,3243,1242,8162,7633,0063,2493,0732,9613,3403,679
Cost of Sales Non-GAAP Adjustments (Intangible Amortization & Restructuring) ($M)($M)
1,2511,2512,227731741656822831672579571585
Non-GAAP Selling, General and Administrative (SG&A) Expense ($M)($M)
2,8872,6682,8482,5992,6332,5292,8192,6572,6842,4572,7512,462
Non-GAAP Research and Development (R&D) Expense ($M)($M)
9,73612,5583,9923,9973,9923,6144,5745,8383,4803,9748,8383,297
Non-GAAP Other (Income) Expense, Net ($M)($M)
290318226531108174133
Non-GAAP Income Tax Provision ($M)($M)
8829579231,0009449318461,1179521,012959
Non-GAAP Effective Income Tax Rate (%)(%)
160.3%-43.5%15.4%13.4%15.0%14.2%16.2%21.9%14.1%16.1%114.2%15.0%
GAAP Effective Income Tax Rate (%)(%)
-95.9%-20.1%13.4%14.2%11.4%13.9%10.2%22.7%9.1%15.9%40.1%15.5%
Other (Income) Expense Breakdown — Interest Income ($M)($M)5
-35-69-96-69-109-146-127-69-73-70-73
Other (Income) Expense Breakdown — Interest Expense ($M)($M)
525412327305313328330310303310317
Other (Income) Expense Breakdown — Foreign Exchange Losses ($M)($M)
37995678904933608316285
Other (Income) Expense Breakdown — (Income) Loss on Equity Securities, Net ($M)($M)
-242196-373-100-9015631-56-143-9933
Other (Income) Expense Breakdown — Net Periodic Defined Benefit Plan (Credit) Cost ($M)($M)
-127-163-152-152-148-157-157-159-160-134-138
Other (Income) Expense Breakdown — Other, Net ($M)($M)
-59-43-69-91-104-272-44-43-91-98
Restructuring Programs — Total Period Charges Across All Programs ($M)($M)3
3344661,277390779105187279176246401199
Restructuring Programs — Total Ending Accrual Reserve ($M)($M)
557564651687736712567
2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M)($M)5
16214821688130105187279177246
2024 Restructuring Program (Supply Network & Commercial Optimization) — Expected Total Program Cost ($M)($M)
4,0004,0004,0004,0004,0004,0004,0004,0004,0004,0004,000
2024 Restructuring Program (Supply Network & Commercial Optimization) — Cumulative Charges Incurred Since Inception ($M)($M)
1,9001,8001,6001,4001,3001,2001,100892613436
2024 Restructuring Program (Supply Network & Commercial Optimization) — Ending Accrual Reserve Balance ($M)($M)
408448506499548564712
2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in Cost of Sales ($M)($M)
999311338653612119266116
2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in Restructuring Line Item ($M)($M)
6355103506469515680123
2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M)($M)4
211199
2019 Restructuring Program (legacy) — Ending Accrual Reserve Balance ($M)($M)
597
2019 Restructuring Program (legacy) — Recorded in Cost of Sales ($M)($M)
5533
2019 Restructuring Program (legacy) — Recorded in R&D ($M)($M)
00
2019 Restructuring Program (legacy) — Recorded in Restructuring Line Item ($M)($M)
127126
Total Inventories — Current & Noncurrent Net ($M)($M)4
12,58812,67412,33911,85611,48310,75210,30210,2399,9259,9239,7069,282
Current Inventories, Net ($M)($M)
6,2076,4796,6586,4446,6016,1966,1096,2446,4696,5106,3586,131
Noncurrent Inventories included in Other Assets — Long-Term ($M)($M)
5,9005,8005,5005,2004,3004,0003,8003,7003,2002,6002,6002,400
Total Gross Inventories before LIFO Reserve ($M)($M)3
13,68913,68113,25112,73912,34211,59811,14211,00110,61210,54410,2689,751
Inventories — Finished Goods ($M)($M)
2,1862,2112,2752,2492,1422,1292,0221,9391,8891,9021,9541,840
Inventories — Raw Materials and Work in Process ($M)($M)
11,19411,13610,64510,1659,8889,1798,8318,7808,4568,3668,037
Inventories — Supplies ($M)($M)
309334331325312290289282267276277281
Inventories — LIFO Reserve Reduction ($M)($M)
1,1011,007912883859846840762687621562469
Finite-Lived Intangible Assets — Products & Developed Technology, Net ($M)1
Product Intangible Asset Carrying Value — Adempas (riociguat) ($M)($M)
203239280312348353372431445533
U.S. Defined Benefit Pension Plans — Funded Status ($M)4
U.S. Defined Benefit Pension Plans — Service Cost ($M)($M)
989899100908910010086868788
U.S. Defined Benefit Pension Plans — Interest Cost ($M)($M)
145145144143141141134134134134130130
U.S. Defined Benefit Pension Plans — Expected Return on Plan Assets ($M)($M)
207207210210210210205206207207182182
U.S. Defined Benefit Pension Plans — Net Periodic Benefit Cost (Credit) ($M)($M)
656651583433424123264137
International Defined Benefit Pension Plans — Funded Status ($M)4
International Defined Benefit Pension Plans — Service Cost ($M)($M)
494857576054616060614848
International Defined Benefit Pension Plans — Interest Cost ($M)($M)
798178787571747473747476
International Defined Benefit Pension Plans — Expected Return on Plan Assets ($M)($M)
158161159159152143138139137139127131
International Defined Benefit Pension Plans — Net Periodic Benefit Cost (Credit) ($M)($M)
-35-22-36-41-19-19-5-7-6-6-15-14
Other Postretirement Benefit (OPEB) Plans — Funded Status ($M)4
Other Postretirement Benefit (OPEB) Plans — Service Cost ($M)($M)
111189910778888
Other Postretirement Benefit (OPEB) Plans — Interest Cost ($M)($M)
161615151616141414141616
Other Postretirement Benefit (OPEB) Plans — Expected Return on Plan Assets ($M)($M)
141411131314202020201616
Other Postretirement Benefit (OPEB) Plans — Net Periodic Benefit Cost (Credit) ($M)($M)
-4-3-13-11-8-8-19-24-21-21-15-15
Organon & Co. — Total Revenues ($M)($M)20
1,5581,4601,5071,6021,5941,5131,5921,5821,6071,6221,5981,519
Organon & Co. — Revenues from Related Party (Merck & Co., Inc. Transition/Supply) ($M)($M)
13,000,00013,000,00014,000,00018,000,00019,000,00018,000,00026,000,00025,000,00028,000,00029,000,00027,000,00028,000,000
Organon Revenue — United States ($M)($M)
398,000,000358,000,000372,000,000406,000,000414,000,000412,000,000416,000,000398,000,000388,000,000371,000,000411,000,000370,000,000
Organon Revenue — Total International ($M)($M)
1,160,000,0001,102,000,0001,135,000,0001,196,000,0001,180,000,0001,101,000,0001,176,000,0001,184,000,0001,219,000,0001,251,000,0001,187,000,0001,149,000,000
Organon Revenue — Europe and Canada ($M)($M)
432,000,000412,000,000406,000,000417,000,000419,000,000376,000,000420,000,000436,000,000457,000,000450,000,000414,000,000392,000,000
Organon Revenue — Asia Pacific and Japan ($M)($M)
232,000,000226,000,000248,000,000251,000,000250,000,000251,000,000244,000,000260,000,000260,000,000287,000,000260,000,000284,000,000
Organon Revenue — China ($M)($M)
208,000,000194,000,000202,000,000219,000,000204,000,000204,000,000213,000,000212,000,000216,000,000206,000,000203,000,000202,000,000
Organon Revenue — Latin America, Middle East, Russia and Africa (LAMERA) ($M)($M)
269,000,000247,000,000262,000,000286,000,000285,000,000240,000,000266,000,000243,000,000251,000,000274,000,000278,000,000239,000,000
Organon Revenue — Other ($M)($M)
19,000,00023,000,00017,000,00023,000,00022,000,00030,000,00033,000,00033,000,00035,000,00034,000,00032,000,00032,000,000
Organon & Co. — Gross Profit ($M)($M)
847783741857874841896923939957915907
Organon & Co. — Cost of Sales ($M)($M)
711677766745720672696659668665683612
Organon & Co. — Selling, General and Administrative (SG&A) ($M)($M)
434424433415453420470422437431469538
Organon & Co. — Restructuring Charges ($M)($M)
0317028680023580
Organon & Co. — Net Income ($M)($M)
108146-2051601458710935919520154658
Organon & Co. — Diluted EPS ($)($)
0.400.550.610.560.331.380.750.780.23
Organon & Co. — Operating Cash Flow ($M)($M)
1072251412642207539014133276397261
Organon & Co. — Capital Expenditures ($M)($M)
423745463932554232467955
Organon & Co. — Cash and Cash Equivalents ($M)($M)
1,1321,116574672599547675763704575693414
Organon & Co. — Inventories ($M)($M)
1,3511,3731,4061,4881,4541,3621,3211,3831,2871,2631,3151,186
Organon & Co. — Total Assets ($M)($M)
13,17812,99612,86713,55213,50013,15613,10112,75212,15411,89112,05811,012
Organon & Co. — Long-Term Debt ($M)($M)
8,4798,5538,6288,7838,7818,9368,8608,7398,6478,7058,7518,646
Organon — Nexplanon / Implanon NXT (contraceptive implant) Worldwide sales ($M)($M)2
230,000,000201,000,000210,000,000223,000,000240,000,000248,000,000259,000,000243,000,000242,000,000220,000,000231,000,000220,000,000
Organon — Nexplanon / Implanon NXT (contraceptive implant) U.S. sales ($M)($M)
129,000,000127,000,000124,000,000146,000,000163,000,000176,000,000175,000,000172,000,000171,000,000153,000,000154,000,000146,000,000
Organon — Nexplanon / Implanon NXT (contraceptive implant) International sales ($M)($M)
101,000,00074,000,00086,000,00077,000,00077,000,00072,000,00084,000,00070,000,00070,000,00067,000,00076,000,00074,000,000
Organon — NuvaRing (contraceptive vaginal ring) Worldwide sales ($M)($M)2
27,000,00024,000,00016,000,00026,000,00028,000,00022,000,00025,000,00023,000,00029,000,00038,000,00039,000,00043,000,000
Organon — NuvaRing (contraceptive vaginal ring) U.S. sales ($M)($M)
9,000,0006,000,000-2,000,0009,000,0007,000,0006,000,0006,000,0007,000,00010,000,00016,000,00020,000,00023,000,000
Organon — NuvaRing (contraceptive vaginal ring) International sales ($M)($M)
18,000,00018,000,00018,000,00017,000,00021,000,00016,000,00018,000,00017,000,00019,000,00022,000,00019,000,00020,000,000
Organon — Follistim AQ / Puregon (fertility) Worldwide sales ($M)($M)2
59,000,00061,000,00058,000,00064,000,00074,000,00069,000,00066,000,00063,000,00062,000,00046,000,00083,000,00054,000,000
Organon — Follistim AQ / Puregon (fertility) U.S. sales ($M)($M)
17,000,00021,000,00023,000,00024,000,00030,000,00035,000,00025,000,00026,000,00022,000,00011,000,00051,000,00022,000,000
Organon — Follistim AQ / Puregon (fertility) International sales ($M)($M)
43,000,00039,000,00035,000,00040,000,00043,000,00034,000,00039,000,00037,000,00040,000,00035,000,00031,000,00032,000,000
Organon — Marvelon / Mercilon (oral contraceptives) Worldwide sales ($M)($M)1
32,000,00026,000,00024,000,00031,000,00033,000,00039,000,00031,000,00029,000,00041,000,00033,000,00037,000,00030,000,000
Organon — Marvelon / Mercilon (oral contraceptives) International sales ($M)($M)
32,000,00026,000,00024,000,00031,000,00033,000,00039,000,00031,000,00029,000,00041,000,00033,000,00037,000,00030,000,000
Organon — Jada System (postpartum hemorrhage device) Worldwide sales ($M)($M)2
05,000,00020,000,00020,000,00018,000,00015,000,00018,000,00016,000,00014,000,00013,000,00012,000,00013,000,000
Organon — Jada System (postpartum hemorrhage device) U.S. sales ($M)($M)
05,000,00020,000,00020,000,00018,000,00015,000,00018,000,00015,000,00014,000,00013,000,00013,000,00012,000,000
Organon — Jada System (postpartum hemorrhage device) International sales ($M)($M)
000000000000
Organon — Renflexis (infliximab-abda biosimilar) Worldwide sales ($M)($M)2
65,000,00057,000,00061,000,00070,000,00063,000,00057,000,00064,000,00072,000,00069,000,00069,000,00077,000,00069,000,000
Organon — Renflexis (infliximab-abda biosimilar) U.S. sales ($M)($M)
44,000,00042,000,00042,000,00051,000,00046,000,00044,000,00052,000,00056,000,00056,000,00055,000,00062,000,00057,000,000
Organon — Renflexis (infliximab-abda biosimilar) International sales ($M)($M)
21,000,00015,000,00020,000,00019,000,00017,000,00012,000,00012,000,00016,000,00013,000,00014,000,00014,000,00012,000,000
Organon — Ontruzant (trastuzumab-dttb biosimilar) Worldwide sales ($M)($M)2
6,000,0005,000,00019,000,00031,000,00031,000,00018,000,00034,000,00020,000,00048,000,00039,000,00062,000,00040,000,000
Organon — Ontruzant (trastuzumab-dttb biosimilar) U.S. sales ($M)($M)
5,000,0004,000,0003,000,0004,000,0005,000,0004,000,0006,000,0005,000,00010,000,0008,000,00010,000,00011,000,000
Organon — Ontruzant (trastuzumab-dttb biosimilar) International sales ($M)($M)
1,000,0001,000,00016,000,00028,000,00026,000,00014,000,00028,000,00015,000,00038,000,00031,000,00052,000,00028,000,000
Organon — Brenzys (etanercept biosimilar) Worldwide sales ($M)($M)1
14,000,00020,000,00021,000,00023,000,00022,000,00014,000,00014,000,00027,000,00012,000,00024,000,00028,000,00013,000,000
Organon — Brenzys (etanercept biosimilar) International sales ($M)($M)
14,000,00020,000,00021,000,00023,000,00022,000,00014,000,00014,000,00027,000,00012,000,00024,000,00028,000,00013,000,000
Organon — Hadlima (adalimumab-bwwd biosimilar) Worldwide sales ($M)($M)1
79,000,00067,000,00069,000,00063,000,00050,000,00047,000,00044,000,00040,000,00028,000,00030,000,00024,000,0008,000,000
Organon — Hadlima (adalimumab-bwwd biosimilar) International sales ($M)($M)
24,000,00016,000,00018,000,00016,000,00014,000,00014,000,00011,000,00011,000,0008,000,0008,000,0008,000,0006,000,000
Organon — Zetia (ezetimibe) Worldwide sales ($M)($M)2
96,000,00087,000,00090,000,00093,000,00074,000,00085,000,00077,000,00081,000,00075,000,00084,000,00069,000,00069,000,000
Organon — Zetia (ezetimibe) U.S. sales ($M)($M)
2,000,0001,000,0001,000,0001,000,0001,000,0001,000,0002,000,0002,000,0002,000,0002,000,0003,000,0002,000,000
Organon — Zetia (ezetimibe) International sales ($M)($M)
95,000,00086,000,00089,000,00091,000,00072,000,00084,000,00075,000,00080,000,00073,000,00082,000,00066,000,00068,000,000
Organon — Vytorin (ezetimibe/simvastatin) Worldwide sales ($M)($M)2
21,000,00021,000,00025,000,00025,000,00027,000,00023,000,00026,000,00026,000,00028,000,00028,000,00029,000,00033,000,000
Organon — Vytorin (ezetimibe/simvastatin) U.S. sales ($M)($M)
1,000,0001,000,0001,000,0001,000,0001,000,0001,000,0002,000,0001,000,0002,000,0001,000,0001,000,0002,000,000
Organon — Vytorin (ezetimibe/simvastatin) International sales ($M)($M)
20,000,00020,000,00024,000,00025,000,00026,000,00022,000,00024,000,00025,000,00026,000,00027,000,00029,000,00031,000,000
Organon — Atozet (ezetimibe/atorvastatin) Worldwide sales ($M)($M)1
80,000,00085,000,00067,000,00095,000,00086,000,00077,000,00077,000,000125,000,000140,000,000132,000,000122,000,000126,000,000
Organon — Atozet (ezetimibe/atorvastatin) International sales ($M)($M)
80,000,00085,000,00067,000,00095,000,00086,000,00077,000,00077,000,000125,000,000140,000,000132,000,000122,000,000126,000,000
Organon — Rosuzet (ezetimibe/rosuvastatin) Worldwide sales ($M)($M)1
5,000,0006,000,0008,000,0006,000,0006,000,0004,000,00013,000,00011,000,0009,000,00016,000,00018,000,00017,000,000
Organon — Rosuzet (ezetimibe/rosuvastatin) International sales ($M)($M)
5,000,0006,000,0008,000,0006,000,0006,000,0004,000,00013,000,00011,000,0009,000,00016,000,00018,000,00017,000,000
Organon — Cozaar / Hyzaar (losartan) Worldwide sales ($M)($M)2
50,000,00057,000,00053,000,00055,000,00056,000,00055,000,00057,000,00059,000,00060,000,00067,000,00056,000,00068,000,000
Organon — Cozaar / Hyzaar (losartan) U.S. sales ($M)($M)
2,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0003,000,0002,000,0003,000,000
Organon — Cozaar / Hyzaar (losartan) International sales ($M)($M)
48,000,00055,000,00051,000,00053,000,00054,000,00053,000,00055,000,00057,000,00058,000,00065,000,00055,000,00065,000,000
Organon — Singulair (montelukast) Worldwide sales ($M)($M)2
48,000,00040,000,00059,000,00053,000,00066,000,00074,000,00084,000,00085,000,00093,000,00098,000,000114,000,00091,000,000
Organon — Singulair (montelukast) U.S. sales ($M)($M)
2,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0003,000,0003,000,000
Organon — Singulair (montelukast) International sales ($M)($M)
46,000,00038,000,00057,000,00051,000,00064,000,00072,000,00082,000,00083,000,00090,000,00095,000,000111,000,00088,000,000
Organon — Nasonex (mometasone) Worldwide sales ($M)($M)2
58,000,00065,000,00065,000,00060,000,00066,000,00072,000,00076,000,00063,000,00060,000,00077,000,00069,000,00060,000,000
Organon — Nasonex (mometasone) U.S. sales ($M)($M)
000000000000
Organon — Nasonex (mometasone) International sales ($M)($M)
58,000,00065,000,00064,000,00060,000,00066,000,00071,000,00076,000,00063,000,00060,000,00077,000,00069,000,00060,000,000
Organon — Dulera (mometasone/formoterol) Worldwide sales ($M)($M)2
41,000,00035,000,00035,000,00034,000,00041,000,00043,000,00052,000,00048,000,00047,000,00056,000,00050,000,00049,000,000
Organon — Dulera (mometasone/formoterol) U.S. sales ($M)($M)
30,000,00023,000,00024,000,00024,000,00032,000,00034,000,00042,000,00038,000,00039,000,00043,000,00040,000,00040,000,000
Organon — Dulera (mometasone/formoterol) International sales ($M)($M)
11,000,00012,000,00011,000,00010,000,0009,000,00010,000,00011,000,00010,000,0008,000,00013,000,00010,000,0009,000,000
Organon — Clarinex (desloratadine) Worldwide sales ($M)($M)2
30,000,00031,000,00030,000,00025,000,00034,000,00034,000,00027,000,00027,000,00035,000,00037,000,00029,000,00028,000,000
Organon — Clarinex (desloratadine) U.S. sales ($M)($M)
1,000,0001,000,0001,000,0001,000,0001,000,00001,000,0001,000,0001,000,0001,000,0001,000,0002,000,000
Organon — Clarinex (desloratadine) International sales ($M)($M)
30,000,00030,000,00029,000,00025,000,00033,000,00034,000,00028,000,00026,000,00035,000,00036,000,00029,000,00026,000,000
Organon — Arcoxia (etoricoxib) Worldwide sales ($M)($M)1
69,000,00059,000,00070,000,00071,000,00063,000,00062,000,00059,000,00069,000,00068,000,00075,000,00050,000,00064,000,000
Organon — Arcoxia (etoricoxib) International sales ($M)($M)
69,000,00059,000,00070,000,00071,000,00063,000,00062,000,00059,000,00069,000,00068,000,00075,000,00050,000,00064,000,000
Organon — Fosamax (alendronate) Worldwide sales ($M)($M)2
25,000,00029,000,00036,000,00040,000,00034,000,00033,000,00039,000,00038,000,00035,000,00040,000,00036,000,00041,000,000
Organon — Fosamax (alendronate) U.S. sales ($M)($M)
1,000,00000001,000,00001,000,0001,000,0001,000,0001,000,0001,000,000
Organon — Fosamax (alendronate) International sales ($M)($M)
24,000,00029,000,00035,000,00040,000,00034,000,00032,000,00038,000,00037,000,00034,000,00038,000,00035,000,00040,000,000
Organon — Diprospan (betamethasone) Worldwide sales ($M)($M)1
44,000,00035,000,00038,000,00041,000,00041,000,00030,000,00037,000,00037,000,00037,000,00029,000,00033,000,00031,000,000
Organon — Diprospan (betamethasone) International sales ($M)($M)
44,000,00035,000,00038,000,00041,000,00041,000,00030,000,00037,000,00037,000,00037,000,00029,000,00033,000,00031,000,000
Organon — Proscar (finasteride — BPH) Worldwide sales ($M)($M)2
20,000,00026,000,00024,000,00027,000,00022,000,00024,000,00022,000,00023,000,00023,000,00026,000,00020,000,00025,000,000
Organon — Proscar (finasteride — BPH) U.S. sales ($M)($M)
000000000000
Organon — Proscar (finasteride — BPH) International sales ($M)($M)
20,000,00026,000,00023,000,00027,000,00022,000,00024,000,00022,000,00023,000,00023,000,00026,000,00020,000,00025,000,000
Organon — Propecia (finasteride — alopecia) Worldwide sales ($M)($M)2
36,000,00030,000,00028,000,00033,000,00032,000,00026,000,00032,000,00028,000,00028,000,00023,000,00033,000,00022,000,000
Organon — Propecia (finasteride — alopecia) U.S. sales ($M)($M)
2,000,0001,000,0002,000,0002,000,0001,000,0001,000,0001,000,0002,000,0002,000,0002,000,0002,000,0002,000,000
Organon — Propecia (finasteride — alopecia) International sales ($M)($M)
34,000,00028,000,00026,000,00031,000,00030,000,00024,000,00031,000,00027,000,00027,000,00021,000,00032,000,00021,000,000
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) Worldwide sales ($M)($M)2
35,000,00025,000,00039,000,00034,000,00031,000,00024,000,00012,000,000000
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) U.S. sales ($M)($M)
34,000,00023,000,00031,000,00031,000,00029,000,00020,000,00010,000,000000
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) International sales ($M)($M)
1,000,0002,000,0008,000,0003,000,0002,000,0004,000,0001,000,000000
U.S. Real Personal Consumption Expenditures — Health Care (SAAR, $B Chained 2017 Dollars)
3,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.403,079.00
DB Segment Context — Pharmaceutical Segment Revenue ($M)($M)4
14,76014,34914,84315,61114,05013,63814,04214,94314,40814,00613,14114,263
Pharmaceutical Segment — Cost of Sales ($M)($M)
1,7311,5531,8411,6641,6011,5731,5091,9041,7081,706
Pharmaceutical Segment — SG&A Expense ($M)($M)
1,4371,3321,5471,4691,3671,4021,6661,5191,5141,429
Animal Health Segment — Cost of Sales ($M)($M)
715675681710659600631613612613
Animal Health Segment — SG&A Expense ($M)($M)
304282303277284260293268270252
DB Geographic Context — Consolidated U.S. Revenue ($M)($M)7
9,3679,1649,13910,0128,8368,5228,1888,7367,8767,4787,0877,715
Geographic Long-Lived Assets — United States ($M)($M)
15,29115,09715,02115,48215,18214,89114,72413,915
Geographic Long-Lived Assets — EMEA ($M)($M)
9,0768,9668,8568,6658,5548,4027,5487,562
Geographic Long-Lived Assets — China ($M)($M)
210213218208204198202193
Geographic Long-Lived Assets — Japan ($M)($M)
129136144147144145143133
Geographic Long-Lived Assets — Asia Pacific ($M)($M)
8508428989489669739821,022
Geographic Long-Lived Assets — Latin America ($M)($M)
131128128139135135133222
Geographic Long-Lived Assets — Other Countries ($M)($M)
505151505149474
DB Income Statement — Consolidated Sales / Revenue ($M)($M)17
16,60716,28616,40017,27615,80615,52915,62416,65716,11215,77514,63015,962
Cost of Sales ($M)($M)
4,3954,1955,5513,8553,5573,4193,8284,0803,7453,5403,9124,264
Selling, General and Administrative (SG&A) ($M)($M)
2,9042,7002,8982,6332,6492,5522,8642,7312,7392,4832,8042,519
Research and Development (R&D) ($M)($M)
9,74112,5923,8864,2344,0483,6214,5845,8623,5003,9929,6273,307
Restructuring Costs ($M)($M)
1511952134756069515680123255126
Other (Income) Expense, Net ($M)($M)
-99-138-432238735-127162-4233-78-126
Interest Income ($M)($M)
353569966910914612769737073
Interest Expense ($M)($M)
525479411327305313328330310303310317
Gain (Loss) on Equity Investments ($M)($M)
242168-19537310090-155-3156143100-33
Income Before Taxes ($M)($M)
-683-3,5343,4206,7454,9995,9034,1704,0906,0065,670-2,0465,620
Taxes on Income ($M)($M)
654709458958571818426929545903-820870
Less: Net Income Attributable to Noncontrolling Interests ($M)($M)
-2-3-1216146505
Net Income Attributable to Merck & Co., Inc. ($M)($M)
-1,335-4,2402,9635,7854,4275,0793,7433,1575,4554,762-1,2264,745
Basic EPS ($)($)
-0.54-1.722.321.762.011.252.151.881.87
Diluted EPS ($)($)
-0.54-1.722.321.762.011.242.141.871.86
Weighted-Average Basic Shares (M)
2,470.002,472.002,495.002,510.002,523.002,534.002,534.002,533.002,537.00
Weighted-Average Diluted Shares (M)
2,470.002,472.002,498.002,513.002,531.002,541.002,544.002,544.002,546.00
Dividends Declared per Common Share ($)($)
0.850.850.850.810.810.810.810.770.770.770.770.73
DB Balance Sheet — Total Assets ($M)($M)27
129,802128,685136,866129,546117,523115,122117,106117,532112,630105,849106,675106,727
Cash and Cash Equivalents ($M)($M)
6,8495,32714,56518,1698,0738,73213,31814,68811,3735,6716,9098,669
Short-Term Investments ($M)($M)
29237504561559944705040252168
Accounts Receivable, Net ($M)($M)1
12,56412,21011,77512,12011,84610,79010,27811,38111,64211,36610,34910,394
Allowance for Doubtful Accounts ($M)($M)
10810397939493897982808885
Inventories ($M)($M)
6,2076,4796,6586,4446,6016,1966,1096,2446,4696,5106,3586,131
Other Current Assets ($M)($M)
10,76710,62410,51810,7799,9969,2898,7068,1438,7407,9508,3686,656
Total Current Assets ($M)($M)
36,67935,01543,51647,55737,06535,50338,78240,36138,20531,44532,16831,954
Property, Plant and Equipment (PP&E), Net ($M)($M)1
25,73725,43325,31625,63925,23624,79323,77923,44623,22123,04523,05122,526
PP&E — Less Allowance for Depreciation ($M)($M)
-22,729-22,288-21,914-20,605-20,256-19,680-19,155-19,072-18,960-18,620-18,266-18,446
Goodwill ($M)($M)
21,58221,58121,57921,58721,59121,68421,66821,69721,16121,18121,19721,183
Other Intangibles, Net ($M)($M)
24,97825,74526,68115,31315,19315,75816,37017,01016,98417,57218,01119,199
Long-Term Investments ($M)($M)
1,2221,1059561,1177746164635753572802521,306
Other Noncurrent Assets ($M)($M)
19,60419,80618,81818,33317,66416,76816,04414,44312,70212,32611,99610,559
Trade Accounts Payable ($M)($M)
3,8273,8634,4044,1473,8923,7844,0793,5863,5193,5143,9223,509
Loans Payable and Current Portion of Long-Term Debt ($M)($M)
2,8252,4442,5891,4051,4341,3602,6493,1493,0713,0771,372887
Income Taxes Payable ($M)($M)
4,2243,9464,7264,8484,1565,1813,9144,3302,7772,3982,6491,981
Accrued and Other Current Liabilities ($M)($M)
14,72514,54914,46816,18614,50212,77215,69416,53914,71214,10215,76614,840
Total Current Liabilities ($M)($M)
27,73126,94528,32728,62826,03725,17428,42029,58626,06025,09925,69423,094
Long-Term Debt ($M)($M)
51,08146,67346,75039,96933,96833,48434,46234,98234,71731,14233,68333,972
Deferred Income Taxes ($M)($M)
1,4331,4941,4391,3811,4271,4091,3878648769228711,018
Other Noncurrent Liabilities ($M)($M)
7,5737,6427,6887,6617,0316,6556,4657,5407,3298,2628,7927,343
Common Stock ($M)($M)
1,7881,7881,7881,7881,7881,7881,7881,7881,7881,7881,7881,788
Other Paid-In Capital ($M)($M)
44,95045,17645,02944,83244,64444,81644,70444,53044,36244,59844,50944,358
Retained Earnings ($M)($M)
63,26966,72173,07572,23168,47766,09763,06961,38460,18756,69753,89557,082
Accumulated Other Comprehensive Loss ($M)($M)
-3,942-4,060-4,287-5,202-5,421-4,965-4,945-5,371-5,361-5,274-5,161-4,916
Treasury Stock, at Cost ($M)($M)
-64,132-63,747-62,999-61,799-60,495-59,401-58,303-57,829-57,394-57,445-57,450-57,066
Merck & Co., Inc. Stockholders' Equity ($M)($M)
41,93345,87852,60651,85048,99348,33546,31344,50243,58240,36437,58141,246
Noncontrolling Interests ($M)($M)
515356576765595866605454
Total Equity ($M)($M)
41,98445,93152,66251,90749,06048,40046,37244,56043,64840,42437,63541,300
DB Cash Flow — Operating Cash Flow ($M)($M)14
5,3703,9182,8577,8223,2932,5003,4509,2915,6373,0902467,717
Capital Expenditures ($M)($M)
8939911,0339877641,328937783791861989902
Depreciation and Amortization ($M)($M)
5995811,448532518502518553518511474452
Stock-Based Compensation ($M)($M)
298185205204216195187195203176167164
Deferred Income Taxes ($M)($M)
-544-315-825-212-448-186-616-401-181-51-931-336
Acquisitions of Businesses, Net of Cash Acquired ($M)($M)
0-8,779-10,0420001,344-5980-74600
Purchases of Securities and Other Investments ($M)($M)
-148-37400-612-595-4550-49-15-251-117
Net Cash Used in Investing Activities ($M)($M)
-5,602-10,210-11,201-283-770-1,487-1,444-3,845-1,069-1,37653-334
Payments on Debt ($M)($M)
-5-1,140-2-10-2,500-53900-751-3-1
Dividends Paid to Stockholders ($M)($M)
-2,144-2,105-2,018-2,031-2,077-2,050-1,951-1,953-1,986-1,950-1,852-1,855
Purchases of Treasury Stock ($M)($M)
-757-874-1,252-1,323-1,345-1,164-489-444-251-122-393-466
Net Cash Used in Financing Activities ($M)($M)
1,762-2,9814,7512,638-3,556-5,755-3,009-2,4251,216-2,814-2,245-4,269
Effect of Exchange Rate Changes on Cash ($M)($M)
-37-192310374156-367294-82-138186-157
Net Increase (Decrease) in Cash and Cash Equivalents ($M)($M)
1,493-9,292-3,57010,187-659-4,586-1,3703,3155,702-1,238-1,7602,957
Cash Paid for Interest ($M)($M)
654342451233383233478241364217422229

252 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: Merck & Co., Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Merck reports two operating segments — Pharmaceutical and Animal Health — while commercial performance is driven by brand-level Worldwide / U.S. / International sales across Oncology, Vaccines, Cardiopulmonary & Hospital Acute Care, Virology, Diabetes, and Animal Health.
  • Core commercial, GTN & R&D KPIs (Groups 1–7) cover: (1) Oncology Portfolio (Keytruda $8,229M WW / $5,088M U.S. / $3,141M Intl in Q2 2026 and $31,680M in FY25; subcutaneous Keytruda Qlex $226M in Q2 2026; Welireg $228M in Q2 2026; Lynparza alliance $398M; Lenvima alliance $273M; Reblozyl royalty $164M; Koselugo alliance $62M); (2) Vaccines Portfolio ($22,554M Total Vaccines in FY25; Gardasil/Gardasil 9 $1,089M in Q2 2026 & China sales breakdown; ProQuad/M-M-R II/Varivax $652M in Q2 2026 with individual Varivax $400M, ProQuad $247M & M-M-R II $119M in Q2 2026 and Q4 = FY − 9M split; Vaxneuvance $262M; Capvaxive $207M; RotaTeq $157M; Pneumovax 23 $35M); (3) Cardiopulmonary, Respiratory & Hospital Acute Care (Winrevair $467M in Q2 2026 / $1,443M in FY25; Ohtuvayre $171M in Q2 2026 following the Verona Pharma acquisition; Adempas/Verquvo Bayer alliance $176M & direct Adempas $85M; Bridion $470M; Prevymis $268M; Dificid; Zerbaxa); (4) Diabetes, Virology & Immunology (Total Diabetes $2,442M in FY25 across Januvia & Janumet; Lagevrio; Isentress; Delstrigo; Pifeltro; Simponi; Remicade; Belsomra; plus pre-spin legacy brands); (5) Animal Health ($1,775M in Q2 2026 / $6,354M in FY25 across Livestock $1,009M and Companion Animal $766M, including Bravecto $396M in Q2 2026 / $1.2B in FY25) & 9-region Pharmaceutical Geographic Sales ($M and % share); (6) U.S. Gross-to-Net (GTN) Customer Discounts Rollforward ($3,907M ending accrual at FY25; $21,375M FY25 provision; $21,150M payments; $2,500M in Q2 2026), 6 Strategic Alliances (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback), and R&D Breakdown (MRL Direct $11.5B vs. Animal Health/BD/Support $6.4B in FY25); and (7) GAAP vs. Non-GAAP Reconciliation, Other (Income) Expense breakdown, and 2024 & 2019 Restructuring Programs.
  • Groups 8–11 cover: (8) Inventories by stage ($12,588M total net current & noncurrent at Q2 2026: Current $6,207M, Long-Term $5,900M, Pre-Launch, Finished Goods $2,186M, Raw Materials & WIP $11,194M, Supplies $309M, LIFO Reserve $1,101M), Drug-Specific Net Intangible Assets (Winrevair $9,424M, Bridion $1,949M, Adempas $203M at Q2 2026), Operating Leases, Defined Benefit Pension & OPEB Plans, and Income Tax / UTB Rollforward ($2,500M UTB at FY25); (9) Global Workforce (30,451 U.S. / 43,722 Non-U.S. employees, 8.5% overall / 5.4% voluntary turnover in FY25), Form 11-K across 3 employee benefit plans (Merck US Savings Plan $13,205M, Puerto Rico Savings Plan $155M, ESPP $376M net assets at FY25, plus Master Trust asset classes), Form SD 3TG Smelters (222 identified / 159 RMAP-conformant in FY25), and Merck Impact Report ESG metrics (48.6M people reached with social investments, 94.3% OTIF, Scope 1/2/3 GHG, energy, water, waste); (10) Spun-Off Subsidiary Self-Disclosed Data for Organon & Co. (NYSE: OGN, CIK 0001821825, spun off June 2, 2021 — P&L, balance sheet, geography, and 24 Women's Health, Biosimilar & Established Brands); and (11) FRED Pharmaceutical & Healthcare Macro Benchmarks and Postgres DB Segment & Financial Statement Context.
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (15)

  • Animal Health (Livestock, Companion Animal, Bravecto) & Pharmaceutical Regions › Animal Health Segment — Worldwide Sales ($M) › Animal Health — Companion Animal (Vaccines & Parasiticides) — Worldwide Sales ($M) › Bravecto (Fluralaner Parasiticides Line) — Quarterly Sales Q1–Q3 ($M; Q4 Not Separately Disclosed) › Bravecto — Worldwide Constant-Currency (Ex-Exchange) Growth YoY (%)
  • Animal Health (Livestock, Companion Animal, Bravecto) & Pharmaceutical Regions › Pharmaceutical Segment — Worldwide Sales ($M) › Pharmaceutical Segment — Total International Sales ($M) › Pharmaceutical Segment — International Reported Growth YoY (%)
  • Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M) › AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Noncurrent Liabilities to Partner ($M)
  • Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) › Eisai Co., Ltd. (Lenvima Oncology Alliance) — Current Payables / Liabilities to Partner ($M)
  • Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) › Eisai Co., Ltd. (Lenvima Oncology Alliance) — Noncurrent Liabilities to Partner ($M)
  • Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) › Eisai Co., Ltd. (Lenvima Oncology Alliance) — Intangible Asset Amortization in Cost of Sales ($M)
  • Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) ($M) › Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Noncurrent Liabilities to Partner ($M)
  • Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) › Daiichi Sankyo (3 DXd ADC Oncology Programs) — Noncurrent Liabilities to Partner ($M)
  • Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) ($M) › Ridgeback (Lagevrio) — R&D Reimbursement from Partner ($M)
  • GAAP vs. Non-GAAP Reconciliation (Table 2a), Other Income/Expense (Table 4) & Restructuring Programs (2024 & 2019 Programs) › Restructuring Programs — Total Period Charges Across All Programs ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in SG&A ($M)
  • GAAP vs. Non-GAAP Reconciliation (Table 2a), Other Income/Expense (Table 4) & Restructuring Programs (2024 & 2019 Programs) › Restructuring Programs — Total Period Charges Across All Programs ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in R&D ($M)
  • GAAP vs. Non-GAAP Reconciliation (Table 2a), Other Income/Expense (Table 4) & Restructuring Programs (2024 & 2019 Programs) › Restructuring Programs — Total Period Charges Across All Programs ($M) › 2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M) › 2019 Restructuring Program (legacy) — Cumulative Charges Incurred Since Inception ($M)
  • Non-Pharma Sources (FRED Benchmarks) & Segments & Financial Statements › Income Statement — Consolidated Sales / Revenue ($M) › Income from Continuing Operations ($M)
  • Non-Pharma Sources (FRED Benchmarks) & Segments & Financial Statements › Cash Flow — Operating Cash Flow ($M) › Proceeds from Sales of Securities and Other Investments ($M)
  • Non-Pharma Sources (FRED Benchmarks) & Segments & Financial Statements › Cash Flow — Operating Cash Flow ($M) › Net Change in Short-Term Borrowings ($M)

Dữ liệu cập nhật 2026-10-26.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Diabetes, Virology, Immunology & Pre-Organon Legacy Brands

Spun-Off Entity Filings — Organon & Co. (NYSE: OGN, CIK 0001821825 — Women's Health, Biosimilars & Established Brands)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Merck

See a number that looks wrong?